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Glial cell line-derived neurotrophic factor (GDNF) is an important signaling
molecule for the somatic motor nervous system. GDNF protein is produced and
secreted by skeletal muscle cells and helps maintain motor neuron innervation at the
neuromuscular junction. Treatment with exogenous GDNF prevents denervation which
is characteristic of aging and neurodegenerative disease. The therapeutic potential of
GDNF cannot be fully explored without understanding the mechanisms by which GDNF
protein production is regulated. The primary objective of this study was to determine the
role of calcium in regulating GDNF protein expression by skeletal muscle cells. Skeletal
muscle cells (C2C12) were grown in culture and allowed to differentiate into myotubes.
The following treatments were given: Bay K8644 (100µM), an agonist for L-type calcium
channels, nifedipine (100µM), a known antagonist for voltage-gated L-type calcium
channels, and dantolene (100µM), an antagonist for ryanodine channels. Results
suggest that expression of GDNF in skeletal muscle is regulated in a calciumdependent manner. Acquiring a greater understanding of the role that calcium plays in
regulating GDNF production may help to identify potential sites for therapeutic
intervention to increase or decrease GDNF production.
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INTRODUCTION
The overarching goal of our laboratory is to gain a more complete understanding
of the communication between neurons and target tissues. Neurotrophic factors have
been discovered as playing a major role in the regulation of innervation of skeletal
muscles, during both development and maintenance of the nervous system. The goal
of the current study is to gain a greater understanding of glial cell line-derived
neurotrophic factor (GDNF) protein expression by skeletal muscle in vitro. We begin
with a brief review of the mammalian neuromuscular system and the neuroprotective
effects of GDNF.

Structure and function of the mammalian nervous system
The nervous system allows animals to receive, interpret, and respond to our
environment. There are two main types of neurons: sensory and motor neurons.
Sensory neurons relay signals from the periphery to the central nervous system (CNS).
The coordinated effort of sensory neurons allows for information sensed from our
environment to travel to places where interpretation of the electrical signals occurs.
Motor neurons relay information from the CNS out to effector organs such as skeletal
muscle. The movement of impulses from the brain through the motor neurons allows
for contraction of muscles for movement.
The motor neurons within the peripheral nervous system are classified as either
somatic or autonomic. The autonomic nervous system consists of both the sympathetic
and parasympathetic nervous systems. The sympathetic nervous system synapses
with smooth muscle and glands and helps stimulate the flight-or-fight response. On the
1

other hand the parasympathetic nervous system acts in a contradictory manner and
helps to regulate homeostasis in the body. The somatic branch of the peripheral
nervous system is used for voluntary movement in skeletal muscles. The majority of
motor neurons that innervate skeletal muscle are α motor neurons, which project from
the CNS to the skeletal muscle fibers and are the largest neurons in the mammalian
nervous system (Huxley, 1974).

Skeletal muscle and neuron interaction
Communication between myelinated motor neurons of the peripheral nervous
system and skeletal muscle occurs at the neuromuscular junction. At the synaptic knob
of the neuromuscular junction, neurotransmitters will mediate depolarization of the
muscle sarcolemma. The action potential will propagate along the sarcolemma and
throughout the transverse tubules, which stimulates a conformational shift in voltagegated L-type calcium channels (v-g L-type Ca2+ channel in figure 1). The L-type Ca2+
channels are in direct contact with foot processes of the ryanodine receptors. Through
depolarization of L-type channels, and their direct interaction with foot processes,
ryanodine receptors along the sarcoplasmic reticulum are opened allowing for calcium
release from internal stores (Catterall, 1991; Mattson, 2007).
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Figure 1: An illustration of the neuromuscular junction. The red arrows indicate the
direction of action potential from the motor neuron to the muscle fiber.

Depolarization of voltage-gated L-type Ca2+ channels within the T-tubule
stimulates the opening of ryanodine channels (RyR Ca2+ channels in figure 1) in the
sarcoplasmic reticulum which act to release internal stores of calcium, further increasing
intracellular calcium levels (Gonzalez- Freire et al., 2014). Due to its direct interaction
with troponin, calcium is an important regulator of skeletal muscle contraction (Berchtold
et al., 2000). In the presence of intracellular calcium, troponin binds to calcium and
moves tropomyosin off the active sites, allowing for myosin heads to bind to actin. Thin
actin filaments and the thick myosin filaments within a sarcomere will then form a sliding
cross-bridge to cause muscle contraction (Huxley, 1974). The presence of calcium at
the neuromuscular junction is necessary for the action potential from the motor neuron
to cause a contractile response in the muscle fiber.
3

Neurotrophic factors
Within the nervous system small proteins called neurotrophic factors help
regulate the development, survival, and functionality of motor neurons (Yan et al., 1993;
Henderson et al., 1996). Neurotrophic factors within the peripheral nervous system can
be made by target tissues such as skeletal muscle, by motor neurons, and by nearby
glial cells. When neurotrophic factors are secreted by muscle tissues they have the
ability to undergo retrograde axonal transportation up to neuronal cell bodies
(Yamamoto et al., 1996; Lie and Weiss, 1998). At motor neurons the neurotrophic
factor exhibits neuroprotective effects and can prevent neuronal cell death.
Neurotrophic factors are proteins that are necessary for the growth,
development, and survival of the mammalian nervous system. Some neurotrophic
factors include nerve growth factor (NGF), neurocytokines, neurotrophin 3, neurotrophin
4/5, brain derived neurotrophic factor (BDNF), and glial cell line-derived neurotrophic
factor (GDNF). The main function of neurotrophic factors is to act as neurocytokines
and, upon synthesis and secretion, to facilitate communication between neurons and
their target tissues (Morcuende et al., 2013). The GDNF family consists of neurturin
(NTRN), artemin (ARTN), persephin (PSPN) and of course GDNF (Lin et al., 1993;
Frostick et al., 1998). Due to the potent effects of GDNF on the peripheral nervous
system the research described herein focuses on this molecule.

GDNF
GDNF was originally discovered in midbrain dopaminergic neurons of SpragueDawley rats (Lin et al., 1993). Shortly after the discovery of GDNF multiple researchers
4

began identifying which cell types in the mammalian body contained and produced
GDNF (Springer et al., 1995). GDNF protein is widely distributed throughout both the
central and peripheral nervous systems. Production and secretion of GDNF occurs in
many cell types such as motor neurons, Schwann cells, skeletal muscle, and within the
kidneys (Henderson et al., 1994; Yan et al., 1995; Yamamoto et al., 1996). Glial cell
line-derived neurotrophic factor is the most potent neurotrophic factor for motor neurons
in the peripheral nervous system and is crucial for the regulation of motor neuron
survival (Henderson et al., 1994).
GDNF is part of the transforming growth factor β (TGF- β) superfamily (Lin et al.,
1993). The members of this family have low amino acid sequence homology but all
function as homodimers for receptor tyrosine kinase activation. All members of the
GDNF family are produced as precursor proteins (preproGDNF) and upon secretion
they are cleaved to the mature protein form (Airaksinen and Saarma, 2002). When first
synthesized there are 211 amino acids in what is called pro-GDNF. This form then
undergoes alternative splicing into the mature form of GDNF protein containing 134
amino acids (Wang et al., 2008). GDNF ligand will bind to GDNFα1 receptor on cell
membranes and activate RET (receptor tyrosine kinase). The downstream signaling of
RET causes activation of many intracellular signaling pathways, such as mitogenactivated protein kinase (MAPK), which has been shown to contribute to both
neurogenesis and neuronal survival (Wang et al., 2008).
Experiments using genetic knockout mice lacking GDNF, RET, or GFRα1 result
in fatalities shortly after birth (Airaksinen and Saarma, 2002). This could be due to many
phenotypic abnormalities including decreased amounts of motor neurons as well as
5

declines in myelination of neurons. When GDNF is absent in the developing embryo of
rodents the kidneys fail to develop properly and in some cases may be completely
absent (Trupp et al., 1995). Another cause of fatality in these knockout mice is
suffocation due to inadequate innervation of the diaphragm. To ensure proper
neuromuscular development the amount and location of GDNF is highly regulated
(Keller-Peck et al., 2001; Oppenheim et al., 1995).
During embryonic development, Schwann cells are the primary producers of
GDNF in the nervous system. In postnatal motor neurons, GDNF production at the
neuromuscular junction supports terminal axon branching and synapse formation
(Airaksinen and Saarma, 2002). Muscle cells express GDNF during development to
promote motor neuron survival. GDNF has been found to play a crucial role during
nervous system development and regeneration by acting as a chemoattractant (Tang et
al., 1998). When target tissues are lacking in innervation they tend to secrete a greater
amount of GDNF into their surrounding environment to attract nearby axons (Nagano
and Suzuki, 2003).
The mammalian nervous system constantly exhibits plasticity beginning
prenatally and continuing during maturation and into aging. During embryonic
development there is typically an overproduction in the amount of neurons needed in
the adult nervous system (Henderson et al., 1994). Motor neuron plasticity allows for
this unnecessary hyper-innervation to undergo modification. As aging continues,
degeneration will occur allowing for each muscle fiber to reach a favorable density of
innervation (Oppenheim et al., 2000; Tintignac et al., 2015). Motor neuron degeneration
is a key stage in development. This process of neuronal retraction is dependent on the
6

presence and absence of target tissues and the corresponding demand for
innervation. One of the methods by which target tissues and neurons can communicate
with each other is through the use of target-derived neurotrophic factors (Oppenheim et
al., 1995; Nguyen et al., 1998).
Neurotrophic factors such as GDNF play a role in maintenance of the
neuromuscular junction. When insufficient levels of GDNF are present, neuronal cell
death can occur, resulting in compromised structure and function of neuromuscular
junctions. Decreased levels of GDNF have been found in association with
neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Duchenne
type muscular dystrophy (DMD) (Suzuki et al., 2008; Yamamoto et al. 1996). Similarly,
when axonal dysfunction or nerve injury occurs GDNF plays a prominent role in the
repair and regeneration of the nervous system (Magill et al., 2010).

GDNF may ameliorate disease and injury
Duchenne type muscular dystrophy and ALS are characterized by progressive
loss of skeletal muscle strength and reduction of muscle fiber innervation. Patients with
DMD displayed a decreased density of neuromuscular junctions in regenerating muscle
fibers and a subsequent up-regulation of GDNF (Suzuki et al., 1998). GDNF remained
elevated until neuromuscular junctions were regenerated. This result suggests that
GDNF may act as a signal between muscle and neurons for inducing and maintaining
innervation following degeneration. Additional research regarding the synthesis of
GDNF may provide improved therapeutic methods, given the ability of GDNF to
ameliorate neuronal degeneration (Deschenes et al., 1993; Suzuki et al., 1998).
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Similarly, an increased expression of GDNF mRNA was found in motor neurons
following denervation of skeletal muscle (Springer et al., 1995). Many studies suggest
that neuroplasticity is a cycle characterized by denervation and retraction of motor
neurons, and subsequent regeneration of the neuromuscular junction. When rates of
denervation outpace rates of reinnervation, a negative phenotype will develop over time
causing decreased functionality of the neuromuscular system. When levels of GDNF
were increased by the addition of exogenous GDNF, neurodegeneration was prevented
in mature neurons (Henderson et al., 1994; Oppenheim et al., 1995). In GDNFoverexpressing transgenic mice, motor neurons displayed greater neuroprotection when
compared to age-matched control animals (Lee et al., 2000).
Researchers used human mesenchymal stem cells to deliver GDNF directly into
skeletal muscle of familial ALS model rats. The rats showed increased muscular levels
of GDNF and retrograde transport of GDNF protein into motor neurons (Suzuki et al.,
2008). Exogenous addition of GDNF demonstrated neuroprotective effects on neuron
survival and function at the neuromuscular junction (Suzuki et al., 2008). A similar
neuroprotective effect was observed in transgenic ALS mice following intramuscular
injection of an adeno-associated virus carrying the gene for GDNF (Wang et al., 2002).
Taken together these studies demonstrate that exogenous administration of GDNF
delays the denervation characteristic of ALS, improves motor performance, and helps
maintain axonal projections to skeletal muscles.
These promising results have prompted investigation to see if GDNF, along with
other neurotrophic factors such as brain-derived neurotrophic factor (BDNF), are able to
prevent the degeneration of dopaminergic neurons in the substantia nigra of
8

Parkinson’s disease (PD) models. A recent study delivered GDNF into the brains of PD
mouse models using GDNF-transfected macrophages (Zhao et al., 2014). Results
revealed that GDNF helped provide protection against neuroinflammation and
neurodegeneration and ameliorated disease pathology (Zhao et al., 2014). Considering
the beneficial effects GDNF has on neurodegenerative disorders it may come as no
surprise that GDNF has also been found to aid in the recovery of motor neurons
following injury.
GDNF was found to be the most potent neurotrophic factor to promote functional
recovery of motor neurons following sciatic nerve injury in rats (Chen et al., 2010; Yan
et al., 1995). Researchers noted differing rates of early regeneration depending on
which cell populations contained GDNF (Magill et al., 2010). Following nerve injury
mice given an injection of GDNF in the target muscle displayed an increased number of
nerve fibers, fiber density, and nerve percentage after two weeks than control mice and
those given injection of GDNF in the neuron (Magill et al., 2010). After three weeks
there was no difference in neuromuscular function between the mice given GDNF
intramuscularly and those given GDNF in the neuron. This information reveals that the
presence of GDNF in skeletal muscle has a greater effect on early regeneration than
GDNF administered to motor neurons. Exogenous administration of GDNF in either
muscles or neurons prompted a more robust recovery in structure and function of the
neuromuscular system (Magill et al., 2010).
In neonatal rats, axotomy of motor neurons innervating extraocular eye muscles
showed varied regeneration depending on the type of neurotrophic factor that was
exogenously added at the site of injury (Morcuende et al., 2013). The results showed
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that NGF, BDNF, NT-3, and GDNF all significantly rescued motor neurons from cell
death with GDNF and NGF as the most potent survival factors for motor neuron
regeneration. Simultaneous administration of GDNF with BDNF resulted in no additive
effect from the positive effect GDNF demonstrated when administered on its own
(Morcuende et al., 2013). Research regarding the high affinity for retrograde axonal
transport by GDNF from muscle to motor neurons compared to other neurotrophic
factors helps support the potent effects of GDNF on motor neuron regeneration (Zhao et
al., 2014). In mature neuromuscular systems the presence of GDNF mRNA and protein
is greatest earlier in development and decreases in an age dependent manner (KellerPeck et al., 2001; Nagano et al., 2003).

Sarcopenia
As mammals age beyond adulthood and into old age there is a notable increase
in sarcopenia. Sarcopenia is the loss of muscle mass and function associated with the
aging process (Frontera et al., 2000). There are many postulated causes of sarcopenia,
ranging from oxidative damage from mitochondrial dysfunction, to age-related
denervation (Edstrom et al., 2007). Recent evidence shows that denervation of motor
neurons precedes sarcopenia and if neuroprotective measures are taken there is a
delay in the age-related changes in skeletal muscle (Deschenes et al., 2010). It is well
documented that with age the plasticity of the neuromuscular system contributes to
muscle fiber type switching. Fast motor neurons typically innervate large type II muscle
fibers and slow motor neurons innervate smaller type I muscle fibers.
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In the mature nervous system fast motor neurons are particularly susceptible to
denervation and retraction. In order to reestablish muscle fiber innervation a nearby
slow type motor neuron may branch out to form a new neuromuscular junction with the
myotube (Edstrom et al., 2007). This change in innervation pattern results in a muscle
fiber switch from a large fast fiber to a slower, smaller, less fatigable muscle fiber. If the
muscle fiber is not reinnervated by either type of motor neuron then the fiber is not
functional and will degrade with time. The loss of neuronal signaling and subsequent
muscle loss contribute to a decline in muscle mass, strength, and overall coordination
(Tintignac et al., 2015).
The onset and extent of sarcopenia with age may be dependent on the amount
of regular muscle activity. In rats aged 21 months the soleus muscle, which is recruited
for daily posture, showed no significant denervation when compared to rats aged 10
months (Deschenes et al., 2010). The plantaris is a skeletal muscle recruited for
locomotion and in this sedentary study there was significant denervation of the elderly
plantaris, without fiber type switching, compared to the young rats. This suggests that
denervation is accelerated with age in muscles that are not recruited but that perhaps
exercise can delay the onset of age-related denervation and subsequent sarcopenia.
There is evidence that the introduction of physical activity may have a neuroprotective
role in preservation of the integrity of the neuromuscular junction (Cheng et al., 2013;
Deschenes et al., 1993). Our lab has found that levels of GDNF protein increase with
exercise, suggesting that physical activity may be used as a method to alter levels of
GDNF regulation and prevent degeneration (McCullough et al., 2011).
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Activity-based neurophysiology
Previous studies from our laboratory demonstrated that the levels of production
of neurotrophic factors may be regulated in an activity-dependent manner. Levels of
GDNF protein extracted from skeletal muscle were greater in rodents subjected to both
voluntary and involuntary physical exercise when compared to sedentary controls
(McCullough et al., 2011; Wehrwein et al., 2002). Similarly, within exercised rats,
GDNF protein levels varied depending on how heavily physical exercise recruited those
muscle groups (Gyorkos et al., 2014). The results revealed that increased muscle
activation resulted in greater intramuscular GDNF protein levels, which suggests that
muscle activity may play a role in determining the expression of GDNF. Similar
increases in GDNF protein can be found in cultured skeletal muscle cells subjected to
electrical stimulation (Vianney et al., 2014).
Physical exercise in mammals has a well-documented positive impact on
neurodegenerative diseases. Dorsal root ganglia extending from the spinal cord
displayed neurotrophic factor-dependent neurite outgrowth following exercise, which
may help ameliorate Parkinson’s disease (Molteni et al., 2004). Interestingly, the
importance of exercise with respect to regeneration of the peripheral nervous system
has received much less attention.
A similar study used nerve transection to examine the role of exercise in nerve
regeneration and protein levels of neurotrophic factors (Park and Hoke, 2014). The
experiment was set up by transecting the median nerve followed by repair. Similarly,
transection of the ulnar nerve was also performed but regeneration was inhibited by
deflecting the ulnar nerve to the biceps muscle (Park and Hoke, 2014). Regeneration
12

was measured by forelimb grip function, motor action potentials, number of axons, and
myofiber size in target muscles (Park and Hoke, 2014). After daily treadmill exercise
there was significantly greater functionality and repair in the peripheral nerves beginning
in as little as 1 week after surgery when compared to the sedentary sham control
recovering mice. Immunocytochemistry showed that the axon number, axon diameter,
and myelin thickness were all significantly greater in the exercise group. After 6 weeks
the mice were sacrificed and GDNF protein levels in the serum, distal nerve, and target
muscles were significantly greater than protein levels in the sedentary mice. This
discovery suggests that exercise may increase generation of neurotrophic factors such
as GDNF to aid in functional and structural regeneration following nerve injury (Park and
Hoke, 2014). The protein levels of GDNF were elevated well after regeneration was
underway which suggests a role for GDNF regarding long term maintenance of
neuromuscular junctions in the peripheral nervous system.

Calcium
As mentioned previously, calcium plays a major role at the neuromuscular
junction and during skeletal muscle contraction. With age, the neuromuscular system
undergoes many notable changes, one of which includes significant alterations in
calcium homeostasis. While the mechanisms underlying changes in the signaling
pathways are currently unknown, there appears to be an age-related development of
abnormal neuronal calcium signaling through calcium channels (Foster, 2007). These
neuronal abnormalities have been observed in the neurodegenerative disorders
13

Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and
Huntington’s disease (Bezprozvanny. 2010).
Alterations in calcium homeostasis contribute to the demise of motor neurons in
ALS (Berchtold et al., 2000). Calcium is a key player in many intracellular pathways so
it is critical that calcium homeostasis is tightly regulated in all cells, particularly in
neurons. The neurons resistant to degeneration in ALS are those which express a
greater amount of Ca2+ binding proteins to prevent excitotoxicity (Mattson, 2007).
Calcium ions play a large role in the release of neurotransmitters at the neuromuscular
junction promoting signaling, neuron excitation, as well as intracellular processes such
as gene expression and programmed cell death (Nikoletopoulou and Tavernarakis,
2012). Deregulation of neuronal Ca2+ homeostasis can lead to declines in both
structure and functionality of neurons in the central and peripheral nervous systems.
The current evidence of altered Ca2+ homeostasis in neurons suggests that calcium
deregulation in target tissues may also contribute to degeneration of the neuromuscular
junction.
Age may affect Ca2+ ion mobility in skeletal muscle cells. Calcium release from
the sarcoplasmic reticulum can occur through RyR1 channels and is necessary for
muscle contraction to occur. In aged rodents RyR1 channels were found to be oxidized
and damaged to the point where they were described as “leaky” with a decline in
functionality when compared to younger adult rodents (Andersson et al., 2011). The
open state of RyR1 channels will act to raise intracellular Ca2+ concentrations and
potentially alter calcium homeostasis. Calcium is critical for the excitation-contraction

14

coupling in skeletal muscles and alterations in the RyR1 receptor can lead to a decline
in specific force production and increase age-dependent muscle weakness (Andersson
et al., 2011). The mechanism responsible for the leak in RyR1 channels as well as the
pathway between Ca2+ alterations and overall muscle weakness has yet to be
determined. It is possible that the link between age-related muscle weakness and
calcium is the neurotrophic factor, GDNF. Because of this, this study is designed to
investigate the role of calcium in regulation of GDNF expression.
While there is a gap in current research examining how calcium ions can regulate
GDNF production in skeletal muscle, there have been studies investigating the role of
calcium in neuronal expression of BDNF. Calcium is a critical component of many
activity dependent signaling pathways in both the CNS and the PNS. The transcription
of GDNF, similar to that of BDNF, appears to be activity-dependent as seen with
changes in physical exercise and electrical stimulation of cell populations (West et al.,
2001). BDNF mRNA expression increases following electrical activity in the brain and
displays a neuroprotective role in adulthood (Allen et al., 2013). After Ca2+ influx from
electrical activity there are a large number of intracellular pathways which can respond
by activating a cascade of intracellular signaling molecules thus amplifying the Ca 2+
signal to the nucleus. Within DNA containing the BDNF gene there is an inactive CREB
(cAMP response element binding protein) bound to the BDNF promoter (West et al.,
2001). Upon CREB phosphorylation, transcription proteins are recruited to the BDNF
promoter and BDNF mRNA is synthesized. In experiments where BDNF CRE or CREB
function was inhibited, there was a dramatic loss of BDNF transcription and BDNF
protein (Tao et al., 1998).
15

While there are a variety of pathways that are able to phosphorylate CREB, they
are all dependent on intracellular calcium influx. Within neurons there are two main
routes for calcium entry. The voltage sensitive calcium channels (L-VSCC) and the
ligand gated ion channel N-methyl-D-aspartate-type glutamate receptor (NMDA-R) are
responsible for a substantial cellular influx of calcium (Tao et al., 1998; West et al.,
2001). Depending on the method of calcium entry there is either a sustained CREB
Ser-133 phosphorylation or a transient CREB Ser-133 induced by L-VSCC and NMDAR respectively. Additionally, this CREB phosphorylation is a developmentally regulated
event during early neuronal development NMDA-R induced expression of earlyintermediate genes occurs following calcium influx. This pathways allows for a transient
increase in BDNF mRNA expression whereas activation of signaling pathways via LVSCC creates a more sustained increase in BDNF expression (Tao et al., 1998; West
et al., 2001). It is possible that a similar calcium-dependent pathway is activated for
GDNF transcription.
Taken together, the previous studies suggest that GDNF expression may be
activity dependent. The overall aim of the current study was to investigate the role of
calcium in regulation of GDNF expression in skeletal muscle.

AIMS OF THE CURRENT STUDY
There are two hypotheses that are explored in the current study. The first
hypothesis is that the use of a calcium channel agonist will increase GDNF expression
by skeletal muscle. The second hypothesis is that the use of calcium channel
16

antagonists will decrease GDNF expression by skeletal muscle. By using both a
calcium channel agonist and antagonists we can promote calcium flux and inhibit
calcium flux respectively, to examine the effects of calcium on GDNF mRNA and protein
levels in skeletal muscle.

MATERIALS AND METHODS
C2C12 mouse myoblast cell line
The C2C12 cell line is a prominently used in vitro model of skeletal muscle
(Richler and Yaffee, 1970). C2C12 cells are myoblasts capable of differentiating into
myotubes. Phenotypically, myotubes exhibit contractile abilities and are capable of
expressing various neurotrophic factors (Vianney and Spitsbergen, 2014). The
experiments described herein utilized the C2C12 cell line at an early passage number
(passage 5-7) and its ability to create and secrete GDNF as a model for mammalian
skeletal muscle.

Cell culture procedures
C2C12 mouse skeletal muscle cells were cultured on 100-mm plates (Falcon) in
89% Dulbecco’s Modified Eagle’s Medium (DMEM; ATTC). In addition to the DMEM,
cell medium was supplemented with 10% fetal bovine serum (Mediatech, Manassas,
VA) and 1% antibiotic-antimycotic (Invitrogen-GIBCO). C2C12 myoblasts were placed
in 37°C incubator with an atmosphere containing 95% atmospheric air supplemented
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with 5% CO2. Cells, cell medium, incubator, and culture hood were kept under sterile
conditions during all experimentation to prevent contamination of cells.
After subculture into 6-well plates (Falcon) C2C12 cells were allowed to reach
100% confluence. At this point in confluency the cell medium was switched to DMEM,
10% horse serum (Sigma), and 1% antibiotic-antimycotic (Invitrogen- GIBCO). Cell
medium was removed by vacuum every 1-2 days. The myoblasts were allowed to
mature into myotubes and at day 5-6 myotubes were subjected to treatment. Myotubes
were treated with cell medium containing Bay K8644 (Bay K), nifedipine, or dantrolene
(100μM) for each treatment for 24 hours prior to sample collection. Samples of
myotubes were taken to examine intracellular GDNF and samples of cell medium were
taken to examine extracellular GDNF levels.

GDNF protein quantification via ELISA
Levels of GDNF protein were quantified by enzyme linked immunosorbent assay
(ELISA). The 96-well ELISA plate (Thermo Scientific) was first coated with GDNF
primary antibody (1μg/mL; R&D Systems) and incubated overnight in a humidification
chamber at room temperature. Each plate was rinsed with wash buffer containing
phosphate buffered saline (PBS, pH 7.4) (deionized water supplemented with 0.9%
NaCl, 0.24% monobasic NaH2PO4, 1.14% dibasic NaH2PO4,) and 0.05% Tween-20.
During all rinses the plate was on low powered plate stirrer. Then a blocking solution of
PBS containing 5% sucrose (MP Biomedicals, LLC) and 1% bovine serum albumin
(BSA: Fisher Scientific) was added to the plate and incubated for exactly one hour.
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Again the plate was rinsed after which the samples were added in the amount of
100μL/well. Samples were added in triplicate and a standard curve was performed. A
standard curve using GDNF protein standard (R&D Systems) was performed during
every ELISA containing samples. The ELISA plate with samples and standard curve
was allowed to incubate for 2 hours. Following incubation, the plate was rinsed and a
secondary antibody solution consisting of Tris buffered saline (TBS pH 7.3), 0.1% BSA,
0.05% Tween-20, and 0.02% anti-GDNF secondary antibody conjugated to biotin (R&D
Systems) was added to the plate. ELISA plates were then incubated overnight and
rinsed. Pierce High Sensitivity Streptavidin HRP (horseradish peroxidase; Thermo
Scientific) was added as 0.5% to a solution containing PBS (pH 7.4) and 1% BSA. This
solution was added to the ELISA plate in the amount of 100μL/well and allowed to
incubate in the humidification chamber for 20 minutes. After this incubation the plate
was rinsed and the color reagent (1-Step Turbo TMB- ELISA; Thermo Scientific) was
added in the amount of 100μL/well. The plate was then placed in the humidification
chamber and after 35 minutes 1M HCl was added to each well in the amount of
100μL/well. All ELISA plates were read by the plate reader at a wavelength of 450nm
immediately following addition of HCl to the color reagent.

Total mRNA extraction from C2C12 cells
ELISA was used for protein quantification and mRNA levels were measured via
real time polymerase chain reaction (qPCR). Cell medium (1mL) was removed from
each well of the 6-well cell culture plate (Falcon) for protein analysis via ELISA. The
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remaining cell medium was removed by vacuum suction in the sterile hood and the cells
were rinsed with 3mL Tyrode’s saline solution per well. The Tyrode’s saline was then
removed and a Trypsin- EDTA (Sigma) solution (90% Tyrode’s saline, 10% EDTA) was
added in the amount of 1mL per well. This solution was sufficient to remove all cells
from the plate, and an equal amount of cell medium (1mL per well) was added to dilute
and inhibit the Trypsin activity. The cells suspended in solution from each well were
transferred to sterile 15mL centrifuge tubes and centrifuged for 5 minutes. TRI Reagent
(1mL; Sigma) was added to each tube containing cells and mixed until cells were
completely homogenized with the solution. An equal portion (1mL) of 95% ethanol was
mixed into the TRI Reagent and cell solution after which 700μL of solution was placed
into an RNase-Free spin column inside an RNase-Free collection tube (Zymo
Research).
The procedure for mRNA extraction was provided by Zymo Research for Directzol RNA MiniPrep Plus as a method for using columns for RNA extraction directly from
TRI Reagent samples. In order to prevent contamination of DNases and RNases, the
work area and all tools were wiped with DNAase Away (Thermo Fisher) and RNaseFree micropipette tips were used (Ambion). All centrifugation steps were performed at
14,000 x g for 30 seconds. RNA Wash Buffer (400μL) was added to each column and
centrifuged again. A DNA digestion buffer solution (6.25% DNase, 93.75% DNA
Digestion Buffer) was added in the amount of 80μL directly to each column and allowed
to incubate at room temperature for 15 minutes. Following incubation, 400μL of Directzol RNA PreWash was added to each column and centrifuged again. The flow-through
was discarded and the collection tube was placed back under the spin column. The
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addition of Direct-zol RNA PreWash (400μL) was added and centrifuged again. After
repeating the Pre-Wash step 700μL of RNA Wash Buffer was added to each column
and centrifuged again but this time for a complete 2 minutes so ensure complete
removal of wash buffer from the samples. Every column was transferred to an RNasefree tube and 100μL of DNase/RNase-Free Water was added and centrifuged for 30
seconds. At this point the extracted RNA was frozen in -80°C until RNA quantification
could occur.

Real time- PCR for mRNA quantification
Immediately prior to qPCR, all samples of RNA were measured with a NanoDrop
2000c UV-Vis Spectrophotometer (Thermo Scientific) to ensure proper levels of RNA
were present after the RNA extraction procedure. DNase/RNase free tips were used to
transfer 1μL of extracted RNA onto the NanoDrop. DNase/RNase free water was used
for calibration. An absorbency ratio of 2.0 for each sample at the 260nm/280nm
wavelengths is generally accepted as “pure” for RNA. Additionally, the NanoDrop was
used to measure the concentration of total RNA extracted and a level greater than 60
ng/uL was deemed appropriate for qPCR.
The procedure for qPCR was provided by Qiagen, as was the QuantiNova SYBR
Green RT-PCR kit (Hilden, Germany). QuiantiTect Primmer Assays (Qiagen) were used
for mouse GDNF (GDNF; Mm_Gdnf_1_SG), beta-actin (Actin; Mm_Actb_1_SG), and
Glyceraldehyde-3-phosphate dehydrogenase (Gapdh; Mm_Gapdh_3-SG). A 96-well
PCR plate (Applied Biosystems) was used and a solution consisting of 10μL of 2x
21

QuantiNova SYBR Green RT-PCR Master Mix, 1μL QN ROX Reference Dye, 0.2μL of
QN SYBR Green RT-Mix, 2μL primer, and 17μL RNase-Free Water was added to each
well in the PCR plate. After the solution was added to the appropriated wells and with
the appropriate primer, 2μL of sample RNA was added to the wells in triplicate. The
PCR plate was covered with optical adhesive covers (Fisher Scientific) the entire plate
was centrifuged at 14,000 x g for 30 seconds to ensure the solution was properly mixed
before adding the plate to the real-time cycler. The cycler (StepOnePlus Real-Time
PCR System by Applied Biosystems) was set for Ct quantification of RNA using SYBR
Green One-Step set up. The cycler conditions were set to 40 cycles at the following
conditions followed by the melt curve analysis. For the reverse transcription step the
temperature was set to 50°C for 10 minutes. The PCR initial activation step was set to 2
minutes at 95°C, followed by a 5 second denaturation step also at 95°C. The combined
annealing extension step was set for 10 seconds at 60°C.
For comparison of the GDNF mRNA between samples the Ct value was
averaged between the triplicate samples. The delta-delta Ct value was calculated for
every sample as outlined by Livak and Schmittgen (Livak and Schmittgen, 2001). This
measurement compares the gene of interest to the housekeeping gene expression to
give delta Ct. The delta Ct is then compared with the delta Ct for the untreated control
samples to give delta-delta Ct. The delta-delta Ct is converted to fold change and the
results were graphed.
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Statistics
Comparisons between multiple groups were made using a one-way ANOVA. A
Tukey’s (Honest Significant Difference) test was used following the ANOVA to
determine any significant difference between two means for GDNF protein data. For
direct comparisons of mRNA levels a student’s T-test was used to determine
significance from vehicle control. A p-value of less than 0.05 was considered
statistically significant for both the ELISA results and the qPCR data. The error bars on
the graphs indicate the standard error of the mean.

RESULTS
Role of L-type Ca2+ channels on myotube GDNF protein levels
Myotubes express voltage-gated L-type calcium channels on the sarcolemma. In
order to examine the role of L-type Ca2+ channels on GDNF protein levels, the agonist,
Bay K8644 (Bay K) was used (figure 2). Bay K acts to increase calcium influx through
voltage-gated L-type Ca2+ channels.
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Figure 2: Effect of Bay K8644 on GDNF protein levels. C2C12 myotubes were
treated with Bay K8644 (100μM) and GDNF levels were measured with ELISA. Results
show that the intracellular GDNF protein levels were increased to 123.9% of control
myotubes (n=8). Extracellular GDNF protein levels were increased to 126.5% of control
(n=4). The values shown here indicate the sample mean ± SEM. The * indicates
significance of p<0.05.

Following 24 hour treatment with Bay K, intracellular levels of GDNF protein were
significantly increased to 124% of control (p<0.05). Extracellular levels of GDNF protein
were increased to 127% of control myotubes (p<0.01). To demonstrate further that
calcium influx through L-type channels affects GDNF levels we chose to examine the
effects of an antagonist for L-type calcium channels on GDNF protein (figure 3).
Treatment with nifedipine (100μM) decreased intracellular GDNF to 65% of
control (p<0.01). Additionally, the protein levels of GDNF found in the surrounding cell
medium was also significantly decreased to 64% of GDNF present in vehicle control
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treated myotubes (p<0.05) (figure 3). There was no significant difference between
intracellular GDNF protein and secreted GDNF.

Nifedipine decreases GDNF protein levels
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Figure 3: Effect of nifedipine on GDNF protein levels. C2C12 myotubes were
treated with nifedipine (100μM) and GDNF was measured with ELISA. Results show
that the intracellular GDNF protein levels were decreased to 65.0% of control (n=16).
Extracellular GDNF protein levels were decreased to 63.5% of control myotubes (n=8).
The values shown here indicate the sample mean ± SEM. The * indicates significance
of p<0.05.

Role of RyR Ca2+ channels on myotube GDNF protein levels
Dantrolene is a known antagonist of ryanodine (RyR) channels within the
sarcoplasmic reticulum. When RyR channels are inhibited there is a lower probability of
calcium release from internal stores. Typically following the depolarization of voltage
gated L-type calcium channels the RyR channels will open to increase intracellular
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calcium levels. Here we demonstrate the effect of a RyR channel antagonist on
intracellular and secreted GDNF protein levels (figure 4).
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Figure 4: Effect of dantrolene on GDNF protein levels. C2C12 myotubes were
treated with dantrolene (100μM) and GDNF was measured with ELISA. Results show
that the intracellular GDNF protein levels were decreased to 23.8% of control (n=5).
Extracellular GDNF protein levels were decreased to 51.0% of control myotubes (n=3).
The values shown here indicate the sample mean ± SEM. The * indicates significance
of p<0.05.

Treatment with dantrolene (100uM) decreased intracellular GDNF protein levels
to 24% of control (p<0.01). Similarly, results showed a significant decrease in
extracellular levels of GDNF protein to 51% of control (p<0.05).
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mRNA levels of GDNF
In addition to examining GDNF protein levels, the expression of GDNF mRNA
was also examined. Real time polymerase chain reaction (qPCR) was used to detect
the levels of GDNF mRNA in untreated control myotubes and in myotubes treated with
calcium channel agonists and antagonists. As predicted, results showed an increase in
GDNF mRNA expression following treatment with Bay K8644 (figure 5). We observed a
significantly increased level of GDNF protein compared to controls and as expected
there was a significant (p<0.01) increase in mRNA. Myotubes treated with the L-type
calcium channel agonist displayed an increase in expression to 211% of control GDNF
mRNA levels (figure 5).
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Figure 5: Effect of Bay K8644 on GDNF mRNA levels. Real time PCR was used to
identify changes in GDNF transcription in C2C12 myotubes following treatment with Bay
K8644 (100μM). Results showed that GDNF mRNA levels were significantly increased
to 211% of control (n=4). The values shown here indicate the sample mean ± SEM.
The * indicates significance of p<0.05.
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As predicted, treatment of myotubes with the L-type Ca2+ channel antagonist,
nifedipine resulted in a decrease in GDNF mRNA compared to control (figure 6).
Results show that the mRNA is significantly decreased following a decline in calcium
flux, these findings support the observed decrease regarding the protein levels. There
was a significant (p<0.01) decline in GDNF mRNA levels to 50% of control mRNA
following inhibition of voltage gated L-type Ca2+ channels (figure 6).
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Figure 6: Effect of nifedipine on GDNF mRNA levels. Real time PCR was used to
identify changes in GDNF transcription in C2C12 myotubes following treatment with
nifedipine (100μM). Results showed that GDNF mRNA levels were significantly
decreased to 50% of control (n=4). The values shown here indicate the sample mean ±
SEM. The * indicates significance of p<0.05.

While there was a strong decline in GDNF protein levels following treatment with
dantrolene, there was no statistically measureable decline in GDNF mRNA (figure 7).
Included in the graph is the sample size of 3 (n=3) with one being 187% of control and
the other 29% of control. The other n was beneath the detection limit of our qPCR
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despite having normal and detectable levels of the two housekeeping genes (Gapdh
and beta-actin). For this reason the graph shows the value for the sample that was
below the detection limit of the assay as 0% of control GDNF mRNA. This very low
mRNA level for GDNF could suggest that there may be a decline in GDNF transcription
following inhibition of RyR receptors but further experiments are necessary (figure 7).

Dantrolene may decrease GDNF expression
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Figure 7: Effect of dantrolene on GDNF mRNA levels. Real time PCR was used to
identify changes in GDNF transcription in C2C12 myotubes following treatment with
dantrolene (100μM). Results showed that GDNF mRNA levels were an average of 72%
from control (n=3). The values shown here indicate the sample mean ± SEM. The
results were inconclusive and there was no significant effect of treatment, likely due to a
low sample size and high variability.
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Figure 8: Overall effects of manipulation of Ca2+ channels on GDNF mRNA. Bay
K8644 caused an increase in expression (* indicates p<0.05 increase from control).
Nifedipine caused a decrease in expression (# indicates p<0.05 decrease from control),
together these show the agonistic and antagonistic effects on L-type Ca2+ channels
respectively. Dantrolene was used as an RyR channel antagonist and GDNF protein
levels were significantly decreased below control. Values in the graph are expressed as
sample means ± SEM.

DISCUSSION
Calcium is a known ion critical for excitation-contraction coupling and has the ability
to act as a potent secondary messenger. The objective of this study was to investigate
the effect that manipulation of calcium flux through L-type Ca2+ channels and RyR
channels has on GDNF expression. Results from these studies suggest a link between
Ca2+ and GDNF expression in myotubes.
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Calcium channel agonist increases GDNF protein levels
Previous studies from our laboratory documented an increase in GDNF protein in
skeletal muscles following exercise in rats (Gyorkos et al., 2014). Similarly, when
C2C12 myotubes were subjected to electrical stimulation GDNF protein levels were
altered (Vianney et al., 2014). Our study used manipulation of L-type Ca2+ channels in
resting myotubes to simulate the calcium flux seen with exercise in skeletal muscle and
observe changes in GDNF.
Bay K8644, a known agonist of L-type Ca2+ channels, has been shown to
promote Ca2+ entry in C2C12 myotubes (Jorquera et al., 2013). Through the use of this
channel agonist, our goal was to determine if increasing calcium flux in resting
myotubes would increase GDNF levels. Other researchers have shown that in primary
cortical neurons and in the PC-6.3 neuroendocrine cell line, GDNF is secreted in a
calcium dependent manner (Lonka-Nevalaita et al., 2010). Our results showed that the
use of a calcium channel agonist significantly increased both intracellular and
extracellular GDNF protein levels (figure 2). This indicates that perhaps the entry of
Ca2+ through L-type channels is similar to the calcium flux seen with excitationcontraction coupling in skeletal muscle and induces similar changes in levels of GDNF
protein. Exploration of the effect of L-type Ca2+ channels on GDNF expression
corroborates findings for an exercise-dependent production of neurotrophic factors by
skeletal muscles (Vianney et al., 2014; McCullough et al., 2011). Physical exercise in
skeletal muscle promotes calcium flux through L-type calcium channels and increases
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GDNF protein levels, a similar effect was observed in the current study though the use
of Bay K.
Lonka-Nevalaita et al. (2010) determined that when neurons were subjected to
KCl-induced depolarization there was an increase in secretion of mature GDNF protein.
This effect was inhibited by use of an extracellular calcium chelator, BAPTA-AM, which
was sufficient to block the increase in GDNF protein secretion (Lonka-Nevalaita et al.,
2010). That study suggests that calcium influx from external stores is necessary to
increase GDNF protein levels in muscle cells, which is consistent with our results
regarding the use of Bay K. Our current study indicates even in the absence of
myotube stimulation, the alteration of calcium channels with agonists created an
increase in GDNF protein levels. Our examination GDNF protein levels did not vary
between intracellular and extracellular levels, compared to control, which suggests that
GDNF may be regulated at the transcription level in resting myotubes as opposed to the
posttranslational secretion of GDNF that Lonka-Nevalaita et al. observed in stimulated
neurons (2010). Following our experiments with a Ca2+ channel agonist, we then
utilized calcium channel antagonists to determine if GDNF protein levels would be
decreased when calcium flux is inhibited in myotubes.

Calcium channel antagonists decrease GDNF protein levels
We examined the effect of inhibiting Ca2+ entry through L-type calcium channels
with nifedipine. As expected, results showed decreased intracellular and extracellular
GDNF protein levels in myotubes following treatment with nifedipine (figure 3). Results
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suggest that when voltage-gated L-type Ca2+ channels are inhibited, there is a
significant decrease in the amount of GDNF protein found within cells and in cell
medium. This is consistent with studies which demonstrated that inhibition of L-type
Ca2+ channels caused decreased transcription of neurotrophic factors (Jorquera et al.,
2013). Our results suggest that when calcium flux through L-type channels is limited,
the effect on GDNF protein levels is similar to the decreased muscular GDNF levels
seen with inactivity (Vianney et al., 2014; Wehrwein et al., 2002). Our study
demonstrated that manipulation of the voltage gated L-type Ca2+ channels with Bay K
and nifedipine was sufficient to alter the protein levels of GDNF by mature myotubes.
As predicted in the hypothesis, the greater Ca2+ flux allowed by open Ca2+ channels
increased GDNF and the decline in Ca2+ mobility created a subsequent decline in
GDNF protein levels.
One of the main influences of L-type Ca2+ channels is to open RyR channels in
the sarcoplasmic reticulum, which release calcium from internal stores (Tao et al., 1998;
West et al., 2001). Release of Ca2+ from the sarcoplasmic reticulum through RyR
channels further increases intracellular calcium levels (Cardenas et al., 2004). We
examined the effect of inhibiting RyR channels using the antagonist, dantrolene, on
GDNF production in myotubes. Other researchers studied the effect of dantrolene in
electrically stimulated hippocampal neurons and determined that dantrolene decreased
extracellular BDNF protein levels (Balkowiec and Katz, 2002). Our results demonstrate
that when RyR calcium channels are inhibited there is a significant decrease in
extracellular GDNF protein levels and a similar decrease in intracellular GDNF protein
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levels (figure 4). Similar to the earlier study our results indicate that inhibition of calcium
release from internal stores can have an effect on neurotrophic factor protein levels.
Balkowiec and Katz (2002) noted that following electrical stimulation there was a
decrease in the amount of BDNF protein secreted into cell medium when dantrolene
was administered to neurons. Their findings suggest that Ca2+ flux through internal
calcium channels plays a role in the secretion of BDNF and our results show an overall
decreased level of GDNF protein in resting myotubes. We utilized a post hoc one-way
ANOVA to determine if there was a significant difference between intracellular GDNF
protein and GDNF protein found in cell medium. Our observations following
manipulation of L-type calcium channels, and with manipulation of RyR channels, found
no significant difference between intracellular and extracellular GDNF protein levels. A
significant difference between intracellular and extracellular GDNF protein levels may
suggest that Ca2+ flux from internal stores could have a role in regulating the secretion
of GDNF protein from skeletal muscle cells.

Calcium channel agonist increases GDNF mRNA
There are many intracellular signaling pathways by which calcium flux can
significantly alter gene expression (West et al., 2001; Nikoletopoulou and Tavernarakis,
2012). Furthermore, the calcium flux observed during depolarization in skeletal muscle,
has the ability to activate a variety of intracellular calcium dependent pathways
(Cardenas et al., 2004). In order to determine if the increase in GDNF protein following
treatment of myotubes with an L-type Ca2+ channel agonist was accompanied by an
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increase in GDNF transcription, we examined levels of GDNF mRNA. Our results
demonstrate that manipulation of calcium flux with a channel agonist is sufficient to
increase GDNF mRNA in myotubes (figure 5). A recent study examined the effects of
electrical stimulation in skeletal muscles following nerve injury and discovered an
upregulation of both GDNF and BDNF mRNA (Willand et al., 2016). This study
suggests that neurotrophic factor transcription may be regulated in an activity
dependent manner and supports our findings that an increase in calcium flux increased
GDNF mRNA levels. Additionally, the study by Willand et al. (2016) suggests that
GDNF and BDNF are similar in that both neurotrophic factors displayed an activitydependent increase in mRNA levels.
Consistent with our results regarding GDNF mRNA, other researchers
discovered that BDNF displays activity- dependent gene transcription via Ca2+ entry
through L-type Ca2+ channels (Tao et al., 1998). The researchers examined BDNF
expression in cultured neurons and found that calcium influx was able to activate the
CREB signaling pathway and induce BDNF gene transcription. Our results show a
similar calcium dependent effect that GDNF expression can be increased in myotubes
by utilizing an L-type Ca2+ channel agonist.

Calcium channel antagonists decrease GDNF mRNA
We discovered that inhibition of calcium flux in myotubes was able to decrease
GDNF mRNA levels. Other researchers have demonstrated the importance of muscle
depolarization and the activity of L-type Ca2+ channels in downstream gene transcription
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(Yamamoto et al., 1996; Yu et al., 2001). Our results show that the use of nifedipine to
inhibit calcium flux through L-type Ca2+ channels significantly decreased levels of GDNF
mRNA (figure 6). These results showed that in the absence of depolarization, or
electrical stimulation, the inhibition of calcium flux was sufficient to decrease GDNF
mRNA in myotubes. Our results suggest that since alterations of voltage-gated Ca2+
channels have an effect on GDNF mRNA that this decrease in expression would be
further amplified following depolarization in myotubes. Gyorkos et al. (2014)
demonstrated that skeletal muscles not recruited during physical exercise failed to
increase GDNF protein content when compared to more heavily recruited muscles.
Other research suggests that RyR receptors within the sarcoplasmic reticulum of
muscle cells play an even more prominent role in gene transcription than L-type Ca2+
channels (Andersson et al., 2013).
Alterations of Ca2+ flux from internal stores can play a role in levels of
neurotrophic factor mRNA. Thapsigargin was used to increase calcium release from
the endoplasmic reticulum in C6 glioblastoma cells (Oh-hashi et al., 2006). Their results
showed that an increase in calcium flux from internal stores caused an increase in
GDNF mRNA. Oh-hashi et al. (2006) demonstrated the potential for Ca2+ flux to
regulate GDNF expression in C6 cells, an observation consistent with our results in
C2C12 cells.
In order to investigate the effect of a RyR channel antagonist on GDNF mRNA
we utilized dantrolene in myotubes. Our results indicate that there was a nonsignificant
effect of dantrolene on production of GDNF mRNA (figure 7). It is possible that a
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greater sample size would lead to a significant decline in GDNF mRNA when
intracellular calcium flux is inhibited. One sample of dantrolene treated myotubes
displayed GDNF mRNA levels beneath the detection limit of our qPCR which suggests
a large downregulation of GDNF without altering mRNA levels of housekeeping genes.
Other researchers have examined the role of calcium flux through RyR channels and its
effect on neurotrophic factors. Within hippocampal neurons inhibition of calcium release
from internal stores, utilizing dantrolene, decreased expression of BDNF (Balkowiec and
Katz, 2002). The significant decrease in GDNF protein following inhibition of RyR
channels, suggests that with additional experimentation there may be a decrease in
GDNF mRNA. Our results suggest that calcium flux through RyR channels in skeletal
muscle may regulate GDNF expression.

Alterations in calcium homeostasis may contribute to neuromuscular dysfunction
A disruption in calcium homeostasis is implicated with sarcopenia. Researchers
discovered that alterations to RyR channel functionality caused changes in intracellular
calcium levels and lead to a decline in force production of skeletal muscle (Andersson et
al., 2011). Our research suggests that calcium flux in myotubes may regulate GDNF
expression. In combination with other studies demonstrating the importance of GDNF
in regulating functionality of the neuromuscular junction it is possible that declines in
regulation of Ca2+ homeostasis contribute to decreased levels of GDNF (Lin et al., 1993;
Morcuende et al., 2013).
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With age there is a decline in the intracellular buffering capacity of neurons and
this disruption of Ca2+ homeostasis can lead to neuronal cell death (Mattson, 2007).
Hormesis is the process of exposing cells to moderate stressors that will result in
adaptive changes for the purpose of protecting the organism from damage associated
with more severe stress. Calcium has the ability to activate hormetic pathways by
activation of CREB by calcium and calmodulin (Mattson, 2007). CREB activation can
then induce expression of neurotrophic factor proteins which will promote neuronal
survival. Our data suggests that the use of the calcium channel agonist, Bay K, causes
an increase in GDNF transcription as evidenced by the increase in GDNF mRNA in
myotubes. A previous study examined the activation of CREB in its ability to regulate
gene expression of brain derived neurotrophic factor (BDNF) in neuronal cells (Tao et
al., 1998). In its inactive form CREB is not phosphorylated and gene expression of
BDNF was inhibited (Tao et al., 1998). The increase of intracellular calcium levels can
activate transcription by phosphorylation of the CREB transcription regulating proteins
followed by expression of BDNF in neurons.
Exercise has been shown to increase both neuronal and muscular levels of
GDNF, however more research into the physiological pathway responsible for this effect
is necessary. It is possible that exercise provides a hormesis effect by enhancing the
ability of muscle cells to regulate Ca2+ homeostasis. The research described herein
demonstrates that the use of Ca2+ channel agonists and antagonists in the absence of
electrical stimulation was sufficient to alter GDNF protein expression in skeletal muscle
cells.
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Other research indicates an age-dependent change in RyR Ca2+ flux (Andersson
et al., 2013). Jimenez-Moreno et al. studied the effect of age on calcium ion release
from the sarcoplasmic reticulum (2008). They discovered that elderly mice exhibited
decreased levels of calcium mobility through RyR channels in the flexor digitorum brevis
muscle when compared to young mice. Similarly, Wang et al. (2000) investigated the
effect of calcium flux in the same muscle in mice following electrical stimulation.
Researchers noted a significant reduction in peak Ca2+ concentration following electrical
stimulation in elderly mice compared to middle and young aged mice. The decrease in
regulation of calcium flux in aged muscle may be due to calcium channel dysfunction.
Calcium leak through RyR channels has been observed in aged muscle leading to
declines in the ability of muscle cells to regulate Ca2+ homeostasis (Andersson et al.,
2013). Our research suggests that dysregulation of normal calcium channels could
contribute to alterations in neurotrophic factor protein and mRNA. Examination of the
extensor digitorum longus muscle in 24 month old rats demonstrated an age-dependent
decline in RyR channel function and a reduction in calcium release from internal stores
(Andersson et al., 2013). It is possible that the reduced skeletal muscle force
production that accompanies RyR channel dysfunction is the result of decreased
neuromuscular plasticity caused by inadequate levels of GDNF protein. Our results
indicate that calcium flux has the ability to regulate GDNF production in skeletal muscle.
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Potential limitations of study
There are a few potential limitations to the previously described studies.
Inhibitors for calcium channels such as nifedipine and dantrolene have been extensively
studied for their ability to limit Ca2+ ion movement in skeletal muscle cells by increasing
the probability of a closed channel state. Similarly, Bay K8644 is an extensively studied
and publicized Ca2+ channel agonist so experimentation to validate its effect on Ca2+ ion
mobility was not performed in this case. A potential limitation to this study could be the
lack of quantification of Ca2+ ion mobility since actual Ca2+ ion levels in cells or
extracellularly were neither measured nor visualized. Another limitation of this study
was the time course for experimentation. At early time points such as 2-6 hours the
levels of GDNF protein were often below the detection limit of our ELISA. For this
reason all samples were taken 24 hours following change of cell medium with chemical
agents and protein levels were within our standard curve even when decreased below
control myotubes GDNF levels. In order to be consistent with the protein data, GDNF
mRNA was extracted from myotubes 24 hours after treatment. It is possible that GDNF
mRNA levels can oscillate in a matter of hours which would not be captured by this
protocol but could be remedied by creating a time course for GDNF expression in
C2C12 myotubes.

Recommendations for future study
One area for future study would be an examination of the time course for GDNF
expression in human skeletal muscle and how this corresponds to in vitro studies.
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Gathering data regarding the normal fluctuations of GDNF during inactivity and physical
exercise in adult mammals would result in a better understanding of the production and
regulation of GDNF over time. This would enable researchers to examine the skeletal
muscle activity dependent alteration of GDNF.
While this study suggests that GDNF expression is a calcium dependent process
in skeletal muscle cells more research is necessary to determine the upstream
regulatory pathway for GDNF expression. This could be accomplished by treating cells
with various signaling molecule inhibitors and monitoring the downstream effects of
such treatments. The study described here suggested that a rise in intracellular Ca2+
ions may result in increased neurotrophic factor expression but further research on
which signaling pathway mediates this effect is necessary to fully document how
physical activity in skeletal muscle alters GDNF production. Since activity-dependent
BDNF transcription occurs through the CREB pathway in neurons, it is possible that
GDNF transcription in myotubes uses the same pathway (Tao et al., 1998). In order to
test the involvement of the CREB pathway in GDNF expression, researchers could
utilize an inhibitor of CREB phosphorylation and activation in skeletal muscle cells, while
quantifying GDNF mRNA and protein.

CONCLUSION

In summary, the results demonstrate that calcium in skeletal muscle cells has the
ability to regulate expression of GDNF. Calcium ions play a large role in skeletal
muscle contraction and Ca2+ flux may regulate GDNF expression. The current studies
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demonstrate that when myotubes are treated with a calcium agonist there is a
significant increase in GDNF mRNA and protein. Similarly, treatment with Ca2+
antagonists resulted in a significant decrease in GDNF mRNA and protein levels. After
examination of L-type channels and RyR channels it appears that a rise in intracellular
Ca2+ levels is necessary to stimulate upregulation of GDNF above vehicle control levels.
Similarly, a decline in intracellular Ca2+ levels was determined to correlate with a
significant decrease in GDNF expression. Considering the highly regulated Ca 2+
homeostasis that occurs in all cell types and the novel information presented here it is
perhaps unsurprising that disruptions in Ca2+ ion levels may alter the structure and
function of the mammalian neuromuscular junction by altering levels of GDNF.
In aging mammals there is often progressive muscle weakening and neuronal
degeneration. These unfortunate effects of aging are often times accelerated in people
with neurodegenerative diseases. Disruptions in Ca2+ homeostasis in neurons is
associated with a variety of neurodegenerative disorders such as Alzheimer’s disease,
Parkinson’s disease, and amyotrophic lateral sclerosis (Bezprovanny, 2010; Mattson,
2007). Research on alterations of neurotrophic factors with neurodegenerative
disorders corroborates the current findings that Ca2+ ion mobility can alter the amount of
GDNF produced by skeletal muscles. If GDNF is not made by the skeletal muscle and
transported to a nearby motor neuron denervation of the muscle may occur resulting in
a decline in muscle strength and coordination.
There are many physiological changes that occur with age and recent research
suggests that dysregulation of Ca2+ homeostasis may be one factor contributing to
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sarcopenia. Age-dependent skeletal muscle weakness can result from leaky RyR
channels in the sarcoplasmic reticulum of rodents (Andersson et al., 2011). Disruptions
of calcium homeostasis in skeletal muscle can lead to muscle weakness and, as the
current study determined, can also lead to alterations in neurotrophic factor production.
Fortunately, researchers have studied mechanisms to prevent or delay the
negative age-related neuromuscular changes typical in mammals. Physical exercise in
rats provides a delay in the onset of sarcopenia and has neuroprotective effects
(Deschenes et al., 2010; Tintignac et al., 2015). Furthermore, exercise helps to
preserve the integrity and functionality of the neuromuscular junction and research from
our laboratory indicates an increase in GDNF protein with exercise (Cheng et al., 2013;
McCullough et al., 2011; Gyorkos et al., 2014). In addition to measuring GDNF protein,
current research from our laboratory has provided information regarding GDNF mRNA.
The overall goal of the study described here was to gain a better understanding of the
regulation of GDNF expression in target tissues. Through investigation of Ca2+ channel
manipulation it appears that there is now an understanding for why physical exercise in
skeletal muscle cells would have a positive downstream effect on GDNF production.
Further research will be required to determine the exact signaling pathway for GDNF
expression in skeletal muscle cells however the current experiments suggest that the
activated pathway is calcium dependent. Understanding GDNF and how cell
populations can be induced to create more GDNF, is a stepping stone which will
hopefully provide a therapeutic effect on preserving the functionality of the human
neuromuscular system in the future.
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